Thailand’s health system is facing challenges from resource constraints including limited budgets, shortages of health professionals, and restricted access to essential medical equipment. At the same time, the system continues to provide low-value care (LVC), which not only fails to deliver meaningf

EXECUTIVE SUMMARY This annual report has been prepared to compile and summarise the activities of the Health Intervention and Technology Assessment Program (HITAP) projects in the past year (2023). It highlights various initiatives aligned with HITAP’s vision, mission, and strategic pillars, guid

This report provides an overview of regional efforts to strengthen HTA capacity across Southeast Asia under the Association of Southeast Asian Nations (ASEAN) Health Cluster 3 (AHC 3) Work Programme. Led by Health Intervention and Technology Assessment Program Foundation (HITAP), in collaboration

Dr. Wanrudee Isaranuwatchai is a Secretary General and Senior Researcher of the Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand. She is also an Affiliated Scientist at St. Michael’s Hospital, and an Associate Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, in Canada.H

Digital health technologies (e.g., wearables, electronic health records, and artificial intelligence tools) are increasingly recognized for their potential to enhance care quality, efficiency, and reach of healthcare services while potentially reducing costs [1]. Landscape reviews have shown increasing investments by governments and other stakehold

68401067EU030L0Carbon resilient,Climate resilient,Green HTA,Health sector

68136067MU028L0medical innovation,health technology assessment,health economic evaluation,target product profiles,research and development

68305067HI027L0Research capacity building,health technology assessment,policy decision making,multidisciplinary research network,international collaboration

It is vital to have evidence-informed clinical practice guidelines or clinical indications to guide the usage of high-cost drugs in the benefits package under the Indonesian universal health coverage (JKN), managed by BPJS Kesehatan. A transparent and legit mechanism is required to support and mo

Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage. Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca